ABSTRACT
BACKGROUND The identification of the metabolic syndrome is essential for a timely diagnosis and to avoid type 2 diabetes, the objective was to determine the validity of the FINDRISC test and glycated hemoglobin for risk screening for diabetes mellitus in a high-altitude resident population (3600 m.a.s.l.) city of La Paz - Bolivia 2018.
METHODS Analytical study of diagnostic tests, the gold test was the definition of metabolic syndrome according to the criteria of the Harmonization Consensus, compared with the FINDRISC test and glycated hemoglobin. People with an age greater than or equal to 18, who agreed to participate, were included. Pregnant women, people with cancer or thyroid disease were excluded.
RESULTS 400 people were included. There were 358 women (89.5%) and 42 men (10.5%) with age of 48.38±14.1 years old. The prevalence of metabolic syndrome was 46.75%. The area under the curve, sensitivity, specificity, positive predictive value and positive likelihood ratio of FINDRISC with cut-off point 10 were 0.7073(CI95% 0.66-0.75), 74.33%(CI95% 67.34-80.30), 67.14%(CI95% 60.33-73.31), 66.51%(CI95% 59.62-72.78) and 2.26(CI95% 1.83-2.79) respectively. With FINDRISC’s (cut-off point 10) and HbA1c (cut-off point 5.7%) together, were 0.8025 (CI95% 0.74-0.84), 88.1%(CI95% 80.82-92.96), 72.41%(CI95% 63.21-80.11), 77.62%(CI95% 69.74-83.98) and 3.19 (CI95% 2.36-4.32) respectively.
CONCLUSIONS The FINDRISC test is a good metabolic syndrome screening test, with a cut point of 10, this is synergized with 5.7% for HbA1c in a high-altitude resident population (3600 m.a.s.l.).
What is already known on this subject?
What is already known on this subject?To exist evidence that FINDRISC test is useful with HbA1c together. It to predict diabetes risk. But there are different cutoff points in both. In high altitude population as La Paz to 3600 m.a.s.l., it doesn’t know.
What are the new findings?
What are the new findings?The FINDRISC test is a good metabolic syndrome screening test, with a cut point of 10, this is synergized with 5.7% for HbA1c in high altitude population as La Paz to 3600 m.a.s.l.
How might these results change the focus of research or clinical practice?
How might these results change the focus of research or clinical practice?The FINDRISC test is easy to apply in primary care, plus the determination of glycosylated hemoglobin, enhances its diagnostic capacity to predict metabolic syndrome, in high altitude resident population, where insulin sensitivity is different.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It does not a clinical trial.
Funding Statement
It was done with UMSA resourses.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study from which this research derives has the ethical endorsement of the Research Ethics Committee IINSAD. This certificate has as date November 17th, 2017.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: pphilco{at}gmail.com
E-mail: aycri_2{at}hotmail.com
E-mail: ismarte7{at}gmail.com
E-mail: angela.alanes{at}gmail.com
E-mail: aivicc3{at}gmail.com
E-mail: omarpayeh{at}gmail.com
E-mail: luz.jaqueline.farah.bravo{at}gmail.com
E-mail: carlosascaso{at}ub.edu
INTRODUCTION. The identification of the metabolic syndrome is essential for a timely diagnosis and to avoid type 2 diabetes, the objective was to determine the validity of the FINDRISK test and glycated hemoglobin for risk screening for diabetes mellitus in a high-altitude resident population (3600 m.a.s.l.) who is a merchant of the city of La Paz - Bolivia 2018. METHODS. Analytical study of diagnostic tests, the gold test was the definition of metabolic syndrome according to the criteria of the Harmonization Consensus, compared with the FINDRISK test and glycated hemoglobin. Merchants from with an age greater than or equal to 18, who agreed to participate, were included. Pregnant women, people with cancer or thyroid disease were excluded. xRESULTS. 430 people were included. There were 382 women (88.8%) and 48 men (11.1%). With age of 49.07 and DS 13.37 years. The prevalence of metabolic syndrome was 46.98%. The sensitivity, specificity and positive predictive value of FINDRISK with cut-off point 10 were 74.3% (CI95% 67.34-80.30), 67.14% (CI95% 60.33-73.31) and 2.26 (CI95% 1.83-2.79), respectively. cut 10 with area under the ROC curve of 0.7073 (CI95% 0.66-0.75). FINDRISK's combined with HbA1c were 85.22% (CI95% 77.10-90.91), 78.57% (CI95% 70.19-85.17) and 3.98 (CI95% 2.82-5.6) respectively, the combined cut-off point of 10 for FINSRISK and 5.9% for HbA1c had an area under the ROC curve of 0.81 (CI95% 0.77 - 0.86). CONCLUSIONS. The FINDRISK test is a good metabolic syndrome screening test, with a cut point of 10, this is synergized with 5.9% for HbA1c.
Data Availability
It is declared that all the data referred to in the manuscript and the links below are available.